Expertise in
15
conditions

Dr. Russell Baur

Hematology | Oncology
Lahey Clinic Hospital, Inc Oncology
41 Mall Rd, 
Burlington, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
18 Years of Experience
Expertise in
15
conditions
Lahey Clinic Hospital, Inc Oncology
41 Mall Rd, 
Burlington, MA 

Overview

Russell Baur is a Hematologist and an Oncologist practicing medicine in Burlington, Massachusetts. He has been practicing medicine for over 18 years.

Dr. Baur is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Chronic Myelogenous Leukemia (CML), Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 6 clinical trials. Dr. Baur is currently accepting new patients.

Graduate Year

2008

Specialties

Hematology
Oncology

Licenses

Internal Medicine in VA

Hospital Affiliations

Winchester Hospital
Lahey Hospital & Medical Center, Burlington
Northeast Hospital Corporation
Beth Israel Deaconess Medical Center
Anna Jaques Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Lahey Clinic Hospital, Inc Oncology
41 Mall Rd, Burlington, MA 01805
Other Locations
Lahey Hospital & Medical Center
41 Mall Rd, Burlington, MA 01805
Lahey Medical Center Peabody
1 Essex Center Dr, Peabody, MA 01960

Additional Areas of Focus

Dr. Baur has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

2 Total Publications

Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim.
Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim.
Journal: European journal of case reports in internal medicine
Published: January 14, 2021
Similar Doctors
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Expertise in
18
conditions
Dr. Steven G. Dubois
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (11.3 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Steven Dubois is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Dubois is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Ewing Sarcoma, Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Osteosarcoma. Dr. Dubois is currently accepting new patients.

Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Expertise in
24
conditions
Dr. Matthew M. Heeney
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (11.3 miles away)
877-442-3324
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Matthew Heeney is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Heeney is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, Hemoglobinopathy, and Splenectomy. Dr. Heeney is currently accepting new patients.

Expertise in
18
conditions
Dr. Akiko Shimamura
Hematology | Oncology
Expertise in
18
conditions
Dr. Akiko Shimamura
Hematology | Oncology
Referral may be required

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 (11.3 miles away)
877-442-3324
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Akiko Shimamura is a Hematologist and an Oncologist practicing medicine in Boston, Massachusetts. Dr. Shimamura is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Shwachman-Diamond Syndrome, Aplastic Anemia, Agranulocytosis, Severe Congenital Neutropenia, and Bone Marrow Transplant. Dr. Shimamura is currently accepting new patients.

Frequently Asked Questions about Dr. Russell Baur

How do I make an appointment with Dr. Russell Baur?

You can book an appointment with Dr. Russell Baur by calling their office at 781-744-8000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Russell Baur a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Russell Baur is classified as an Distinguished expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Russell Baur specialize in?

While Dr. Russell Baur is a Hematology, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), and Chronic Myelogenous Leukemia (CML). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Russell Baur participate in research or clinical trials?

Yes. Dr. Russell Baur has published 2 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Russell Baur's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Russell Baur accept my insurance?

Dr. Russell Baur accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 781-744-8000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baur's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile